301. Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma
- Author
-
Bo Chen, Ningning Lu, Xin-Fan Liu, Liqiang Zhou, Yongwen Song, Shulian Wang, Shunan Qi, Jing Jin, Hua Ren, Zi-Hao Yu, Xi-mei Zhang, Weihu Wang, Yueping Liu, Yexiong Li, Qing-Feng Liu, and Hui Fang
- Subjects
Oncology ,Adult ,Male ,Vincristine ,medicine.medical_specialty ,Cyclophosphamide ,Adolescent ,medicine.medical_treatment ,CHOP ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Survival rate ,Anaplastic large-cell lymphoma ,Aged ,Neoplasm Staging ,Chemotherapy ,business.industry ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Lymphoma ,Survival Rate ,Regimen ,Doxorubicin ,Gamma Rays ,Lymphoma, Large-Cell, Anaplastic ,Prednisone ,Female ,Lymph Nodes ,business ,medicine.drug - Abstract
The aim of this study was to analyze outcomes in adult patients with early stage systemic anaplastic large-cell lymphoma (ALCL) treated with doxorubicin-based chemotherapy and radiotherapy. Forty-six adult patients with early stage systemic ALCL received chemotherapy followed by radiotherapy. All patients except two received chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or a CHOP-like regimen. Twenty patients had stage I disease, and 26 patients had stage II disease. The 5-yr overall survival (OS), progression-free survival (PFS), and local control rates for all patients were 84.4%, 63.6%, and 90.8%, respectively. The 5-yr OS and PFS rates were 95.0% and 77.4% for Ann Arbor stage I disease, and 75.1% and 51.7% for stage II disease, respectively. Lymph node involvement was the main pattern of disease progression or relapse for these patients. Adult patients with early stage systemic ALCL treated with doxorubicin-based chemotherapy and radiotherapy had a favorable prognosis.
- Published
- 2012